Indication: Chronic pain
Conclusion: There is substantial evidence that cannabis is an effective treatment for chronic pain in adults
Indication: Chemotherapy-Induced Nausea and Vomiting
Conclusion: There is conclusive evidence that oral cannabinoids are effective anti-emetics in the treatment of chemotherapy-induced nausea and vomiting
Conclusion: There is insufficient evidence to support or refute the conclusion that cannabinoids are an effective treatment for epilepsy
Indication: Spasticity Associated with Multiple Sclerosis or Spinal Cord Injury
Conclusion: There is substantial evidence that oral cannabinoids are an effective treatment for improving patient-reported multiple sclerosis spasticity symptoms, but limited evidence for an effect on clinician-measured spasticity
Indication: Sleep disorders
Conclusion: There is moderate evidence that cannabinoids, primarily nabiximols, are an effective treatment to improve short-term sleep outcomes in individuals with sleep disorders associated with obstructive sleep apnea syndrome, fibromyalgia, chronic pain, and multiple sclerosis
For epilepsy, there is insufficient evidence, but we refer to the FDA approval of investigational new drug studies of Epidiolex/CBD for anti-seizure for Dravet and Lennox-Gastaut syndromes (epilepsy).
Psoriasis is not covered by (NAP, 2017), but a recent review (Mounessa, 2017) and (Wilkinson, 2007) points to the use of cannabinoids in dermatology and psoriasis.
Mounessa, 2017. Mounessa JS, Siegel JA, Dunnick CA, Dellavalle RP (2017): The role of cannabinoids in dermatology.J Am Acad Dermatol, 77, 188-90.
Wilkinson, 2007. Wilkinson JD and Williamson EM (2007): Cannabi-noids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatolog Sci, 45, 87-92.